Stockreport

Structure Therapeutics Posts 15%+ Weight Loss in ACCESS II for Oral GLP-1 Aleniglipron, Eyes Phase III [Yahoo! Finance]

Structure Therapeutics Inc.  (GPCR) 
PDF mg) and 15.0% (240 mg) at week 44, with placebo-adjusted reductions near for the 180 mg and 240 mg arms and strong categorical responses (93% =10% loss and 61% =15% at 1 [Read more]